Danyu Du

National Key Laboratory For Multi Target Natural Drugs
Nanjing, 210009, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

C118P Suppresses Gastric Cancer Growth via Promoting Autophagy-Lysosomal Degradation of RAB1A.

C118P Suppresses Gastric Cancer Growth via Promoting Autophagy-Lysosomal Degradation of RAB1A.

Journal: Pharmaceutics

Published: November 24, 2024

RHNO1 disruption inhibits cell proliferation and induces mitochondrial apoptosis via PI3K/Akt pathway in hepatocellular carcinoma.

RHNO1 disruption inhibits cell proliferation and induces mitochondrial apoptosis via PI3K/Akt pathway in hepatocellular carcinoma.

Journal: Biochemical and biophysical research communications

Published: May 20, 2023

Determining the In Vitro Ligand-Target Interaction by Cellular Thermal Shift Assay and Isothermal Dose-Response Fingerprint Assay.

Determining the In Vitro Ligand-Target Interaction by Cellular Thermal Shift Assay and Isothermal Dose-Response Fingerprint Assay.

Journal: Bio-protocol

Published: January 15, 2023

RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression.

RNA binding motif protein 45-mediated phosphorylation enhances protein stability of ASCT2 to promote hepatocellular carcinoma progression.

Journal: Oncogene

Published: December 17, 2022

GPR27 Regulates Hepatocellular Carcinoma Progression via MAPK/ERK Pathway.

GPR27 Regulates Hepatocellular Carcinoma Progression via MAPK/ERK Pathway.

Journal: Cancer management and research

Published: August 24, 2021

Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.

Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.

Journal: Acta pharmaceutica Sinica. B

Published: April 08, 2021

C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.

C118P, a novel microtubule inhibitor with anti-angiogenic and vascular disrupting activities, exerts anti-tumor effects against hepatocellular carcinoma.

Journal: Biochemical pharmacology

Published: March 13, 2021

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.

Journal: Acta pharmaceutica Sinica. B

Published: January 11, 2021

The comprehensive landscape of miR-34a in cancer research.

The comprehensive landscape of miR-34a in cancer research.

Journal: Cancer metastasis reviews

Published: December 17, 2020

The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer.

The structure and regulation of the E3 ubiquitin ligase HUWE1 and its biological functions in cancer.

Journal: Investigational new drugs

Published: December 06, 2019

Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner.

Sepiapterin reductase promotes hepatocellular carcinoma progression via FoxO3a/Bim signaling in a nonenzymatic manner.

Journal: Cell death & disease

Published: November 05, 2019

MHP-1 inhibits cancer metastasis and restores topotecan sensitivity via regulating epithelial-mesenchymal transition and TGF-β signaling in human breast cancer cells.

MHP-1 inhibits cancer metastasis and restores topotecan sensitivity via regulating epithelial-mesenchymal transition and TGF-β signaling in human breast cancer cells.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology

Published: January 19, 2016

Showing 1-12 of 12

Last Updated: 09/26/2026